Inhibition of platelet aggregation refers to the prevention and treatment of various thrombotic and embolic disorders by inhibiting the ability of platelets to aggregate together with medications. Platelets have many physiological properties, including aggregation, which refers to the ability of platelets to aggregate with each other to form platelet thrombi for the purpose of stopping bleeding. However, if the platelet thrombus aggregates excessively, it will easily form thrombotic diseases, leading to the formation of coronary heart disease, myocardial infarction, cerebral thrombosis, lower extremity venous thrombosis and a series of other diseases. Inhibiting platelet aggregation through drugs can effectively prevent thrombotic and embolic diseases. The drugs commonly used in clinical practice to inhibit platelet aggregation include aspirin, Polivy, etc. These drugs inhibit platelet aggregation through different mechanisms, thus preventing the occurrence of various diseases.